DMK Pharma Says Contaminated Injectors Led To Ch. 11 Filing

By Yun Park · May 31, 2024, 2:51 PM EDT

Drugmaker DMK Pharmaceuticals Corp. has filed an adversary complaint in Delaware bankruptcy court, saying its epinephrine-injector supplier failed to maintain contaminant-free manufacturing facilities sold to the debtor, which caused one of...

To view the full article, register now.

Bankruptcy Scorecard


DMK Pharmaceuticals has applied for Chapter 11 protection in Delaware, citing recent clinical trial failures and product recalls, as well as the government's allegation that a subsidiary engaged in criminal activities, as reasons for seeking bankruptcy relief.

Case Number



Mary F. Walrath


U.S. Bankruptcy Court for the District of Delaware

Capital Structure

Total Liabilities:


View Full Scorecard